A pharmaceutical composition comprising a PGI2 receptor agonist and its use therein.
By combining PGI2 receptor agonist compounds with sildenafil in a specific ratio, synergistic effects are achieved in inhibiting pulmonary hypertension, overcoming the shortcomings of existing drugs in long-term efficacy and providing a more effective treatment option.
Patent Information
- Application Number
- CN202411212107.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-06
- Filing Date
- 2024-08-30
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-08-30
AI Technical Summary
Existing single-drug therapies for pulmonary arterial hypertension (PAH) have failed to effectively reverse or halt disease progression in the long term, necessitating combination therapies to provide better treatment options.
By combining a PGI2 receptor agonist compound with sildenafil in a specific molar ratio, the two drugs synergistically inhibited K+-induced increase in pulmonary artery ring tension and PDGF-induced proliferation of human pulmonary artery smooth muscle cells.
It enhances the efficacy against pulmonary arterial hypertension, especially in patients with moderate to severe PAH who cannot be controlled by existing drug combinations, and is significantly superior to the combination of selexipargan and sildenafil, providing a better combination therapy for pulmonary arterial hypertension.
Smart Images

Figure CN119033791B_ABST
Abstract
Description
[0001] Cross-reference to related applications This application claims priority to Chinese patent application CN202311824286.0, filed on December 27, 2023, and to Chinese patent application CN202410169645.1, filed on February 6, 2024, the full text of which is incorporated herein by reference. Technical Field
[0002] This invention belongs to the field of drug combination therapy, specifically relating to a pharmaceutical composition containing a PGI2 receptor agonist and its use. Background Technology
[0003] Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease characterized by vasoconstriction and vascular remodeling (i.e., intimal hyperplasia, medial hypertrophy, and fibrosis) within the pulmonary arterioles, leading to a gradual increase in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR), often resulting in fatal right heart failure. The pathogenesis of PAH is not fully understood. Endothelial damage caused by external stimuli (such as hypoxia or anorexia) or systemic processes (such as connective tissue diseases) can trigger neurohormonal imbalances in susceptible individuals and is considered a focal point or lesion for disease progression. The result is an overproduction of mediators such as endothelin-1, angiotensin II, thromboxane A2, and serotonin, leading to vasoconstriction, smooth muscle cell proliferation, and increased profibrotic and / or prothrombotic effects. Simultaneously, the production of nitric oxide (NO) and prostacyclin (PGI2) is reduced; this imbalance ultimately leads to pulmonary vascular disease.
[0004] The mechanisms that facilitate these pathological effects are complex. This complexity is highlighted by the fact that these mediators operate through numerous overlapping secondary messenger systems. Given this inherent redundancy, many drugs used to treat PAH show short-term efficacy but, in the long run, "fail to meet the standard" in reversing or halting the progression of the disease.
[0005] The redundancy of this pathway justifies the use of combinations of drugs with different mechanisms of action to treat PAH. Combination therapy, involving existing therapies or new drug combinations with improved pharmacodynamic properties, represents a new clinical paradigm for patients with suboptimal responses, further reducing PAH-related morbidity and mortality.
[0006] Therefore, there is a clinical need to find combination drug combinations for the treatment of pulmonary hypertension, so as to provide more and better medication options for patients with different disease conditions. Summary of the Invention
[0007] In view of this, the present invention provides a combination pharmaceutical composition for treating pulmonary hypertension and its application.
[0008] To address the aforementioned technical problems, one object of the present invention is to provide a pharmaceutical composition comprising a first active ingredient and a second active ingredient, wherein the first active ingredient is a PGI2 receptor agonist compound represented by general formula I or a pharmaceutically acceptable salt thereof, and the second active ingredient is sildenafil; the compound represented by general formula I or a pharmaceutically acceptable salt thereof is a PGI2 receptor agonist.
[0009]
[0010] In the formula, R1 and R2 are independently selected from H, C1-C3 alkyl or halogen atoms; Z is selected from CR7 or N atoms, wherein R7 is selected from H or C1-C3 alkyl, halogen atom or halo-C1-C3 alkyl; R3 is selected from C2-C4 alkyl groups, C 3- C6 monocyclic cycloalkyl; R4 is selected from H, C1-C3 alkoxy groups, or 3-6 membered heterocyclic groups; R5 represents OH, OR6, or NHSO2R6, where R6 represents C. 1-4 Alkyl or halogen-substituted C 1-4 Alkyl groups; carboxyl groups react with R5 to form acids, esters, or sulfonamides; Indicates a single bond or a double bond.
[0011] In one embodiment, the compound of general formula I or a pharmaceutically acceptable salt thereof, wherein Z is an N atom; or Z is CR7, where R7 is selected from H or CH3.
[0012] In one of the implementation schemes, Representing a double bond, R4 is H, and its structural formula is shown in Equation II:
[0013] In Formula II, R1 and R2 are selected from H, methane, or F; Z is an N atom, or Z is CR7, and R7 is selected from H or CH3, more preferably H; R3 is selected from isopropyl, ethyl, or cyclopropane, more preferably isopropyl; R5 is selected from OH or NHSO2R6, and R6 is selected from C 1-4 Alkyl or halogen-substituted C 1-4 Alkyl, R6 more preferably methyl.
[0014] In one of the implementation schemes, This represents a single bond, and its structural formula is shown in Equation III:
[0015] In Formula III, R4 is selected from H, C1-C3 alkoxy, or 3-6 membered heterocyclic cycloalkanes, preferably H, methoxy, ethoxy, or... More preferably, R4 is H, methoxy, or ethoxy.
[0016] In one embodiment, the compound of general formula I or general formula III or a pharmaceutically acceptable salt thereof is involved, wherein R1 and R2 are selected from H, methane or F; Z is an N atom, or Z is CR7, R7 is selected from H or CH3, more preferably an H atom; R3 is selected from isopropyl, ethyl or cyclopropane, preferably R3 is isopropyl; R5 is preferably OH or NHSO2CH3.
[0017] The compounds of general formula I are selected from, but not limited to, the specific compounds (1)-(15) with the following structural formulas. The code names of each specific compound are also shown in the structural formula. Compounds (1)-(15) are named SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN013, SYN010, SYN017, SYN044, SYN046, SYN018, and SYN045, respectively.
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026] Information regarding the chemical names and preparation methods of the above-mentioned compounds of general formulas I, II, and III and their pharmaceutically usable salts, as well as the specific compounds (1)-(14) and their pharmaceutically usable salts, is disclosed in the Chinese patent application document CN202410701014.X. Information regarding the chemical name and preparation method of the specific compound (15) and its pharmaceutically usable salt is disclosed in the Chinese patent application document CN202410701022.4.
[0027] Through extensive experiments, the inventors discovered that the PGI2 receptor agonist compound or specific compound (1)-(15) shown in general formula I, when used in combination with sildenafil, exhibits strong synergistic anti-pulmonary hypertension activity, thereby enhancing the anti-pulmonary hypertension activity.
[0028] The PGI2 receptor agonist compound or specific compound (1)-(15) shown in Formula I, when used in combination with sildenafil, has a synergistic effect on inhibiting K+-induced increase in pulmonary artery ring tension and / or inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells. The pharmaceutical composition is more helpful in the treatment of pulmonary hypertension that cannot be resolved by monotherapy.
[0029] In some embodiments, the molar ratio of the first active ingredient to the second active ingredient is 1:4-12:1; the preferred molar ratio of the first active ingredient to the second active ingredient is 1:3-10:1; further preferred molar ratios are 1:3, 4:1, or 10:1; and more preferably a molar ratio of 4:1, at which the combination index (CI) value is relatively lower and the synergistic effect is stronger. In some embodiments, the first active ingredient in the pharmaceutical composition is a specific compound (1).
[0030] Furthermore, the molar ratio of the specific compound (1) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.
[0031] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (2).
[0032] Furthermore, the molar ratio of the specific compound (2) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.
[0033] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (3).
[0034] Furthermore, the molar ratio of the specific compound (3) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.
[0035] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (4).
[0036] Furthermore, the molar ratio of the specific compound (4) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1, and more preferably 10:1.
[0037] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (5).
[0038] Furthermore, the molar ratio of the specific compound (5) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1, and more preferably 1:3.
[0039] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (6).
[0040] Furthermore, the molar ratio of the specific compound (6) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1, and more preferably 4:1.
[0041] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (7).
[0042] Furthermore, the molar ratio of the specific compound (7) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1, and more preferably 10:1.
[0043] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (8).
[0044] Furthermore, the molar ratio of the specific compound (8) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1, and more preferably 1:3.
[0045] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (9) with the code name SYN013.
[0046] Furthermore, the molar ratio of the specific compound (9) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1, and more preferably 1:3.
[0047] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (10) with the code name SYN010.
[0048] Furthermore, the molar ratio of the specific compound (10) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1, and more preferably 10:1.
[0049] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (11) with the code name SYN017.
[0050] Furthermore, the molar ratio of the specific compound (11) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.
[0051] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (12), code name SYN044.
[0052] Furthermore, the molar ratio of the specific compound (12) to sildenafil is 1:3-10:1, preferably 1:3-4:1, and more preferably 1:3 or 4:1.
[0053] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (13), code name SYN046.
[0054] Furthermore, the molar ratio of the specific compound (13) to sildenafil is 1:3-10:1, preferably 1:3-4:1, and more preferably 1:3 or 4:1.
[0055] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (14) with the code name SYN018.
[0056] Furthermore, the molar ratio of the specific compound (14) to sildenafil is 1:3-10:1, preferably 1:3-4:1, and more preferably 1:3 or 4:1.
[0057] In some embodiments, the pharmaceutical composition wherein the first active ingredient is a specific compound (15) with the code name SYN045.
[0058] Furthermore, the molar ratio of the specific compound (15) to sildenafil is 1:3-10:1, preferably 1:3, 4:1 or 10:1.
[0059] The synergistic effect of the PGI2 receptor agonist compound or specific compounds (1)-(15) of general formula I, when used in combination with sildenafil at the above-mentioned specific ratio and test concentration, is stronger than that of the combination of the existing drug selexipag and sildenafil in inhibiting K+-induced increase in pulmonary artery ring tension and / or inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells. Therefore, the combined drug composition is more effective against pulmonary hypertension and is more helpful in the treatment of moderate to severe pulmonary hypertension patients whose condition cannot be controlled by the existing drug combination of selexipag and sildenafil.
[0060] In some embodiments, the pharmaceutical composition further includes a pharmaceutically acceptable carrier and / or excipients; and its dosage form may be a tablet, granule, capsule, powder, or injection.
[0061] Another object of the present invention is to provide the use of the above-described pharmaceutical composition in the preparation of a combination medicament for treating pulmonary hypertension. Attached Figure Description
[0062] Figure 1 The combined drug index CI dot plot is a comparison of the ring tension inhibition rate of isolated pulmonary artery rings when PGI2 receptor agonist compounds (1)-(15) and selepag were combined with sildenafil (4:1) in Experiment Example 1. Figure 2 The CI dot plot is a comparison of the inhibition rate of human pulmonary artery smooth muscle cell proliferation by PGI2 receptor agonist compounds (1)-(15) and selepag in combination with sildenafil (1:3) in Experiment Example 2. Detailed Implementation
[0063] The present invention will be further described in detail below through specific embodiments, but this is only for the purpose of helping to understand the present invention and enabling those skilled in the art to implement or use the present invention, and does not constitute any limitation on the present invention.
[0064] Compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN013, SYN010, SYN017, SYN044, SYN046, and SYN018 were prepared according to the preparation methods of Examples 1-14 in Patent CN202410701014.X, and compound SYN045 was prepared according to the preparation method of Example 1 in Patent CN202410701022.4.
[0065] Purchased commercially available selepag active pharmaceutical ingredient from Cangzhou Enke Pharmaceutical Technology Co., Ltd., batch number 20221231; purchased commercially available sildenafil active pharmaceutical ingredient from Beijing Solarbio Co., Ltd., batch number S6070.
[0066] Example The PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045 and SYN046 were formulated with sildenafil in molar ratios of 10:1, 4:1 and 1:3, respectively, to form combination drug compositions.
[0067] The following experiments were conducted on the isolated pulmonary artery ring tension and the inhibition rate of human pulmonary artery smooth muscle cell proliferation of the above-mentioned multiple combined drug combinations.
[0068] Experimental Example 1: Comparative Study of the Tension of Isolated Pulmonary Artery Rings When Combined with PGI2 Receptor Agonists and Sildenafil 1. Experimental procedure: S1: Rats were anesthetized by intraperitoneal injection of 25% urethane (5 mL / kg). The heart and lungs were separated by thoracotomy. The pulmonary artery vessels were isolated under a microscope, and vascular rings with a length of 2-3 mm were prepared and hung on hooks on tension transducers. The prepared pulmonary artery vascular rings were immersed in incubation solution and finely adjusted to a basic tension of about 0.8-1 g. After stabilization for 1-2 hours, the basic tension was measured.
[0069] S2: Using a high-K+ incubation solution, the tension of the pulmonary artery vascular ring was increased, and the maximum tension induced by high-K+ in the pulmonary artery vascular ring was recorded.
[0070] S3: Then, incubation solutions and the drug combination to be tested were added to multiple incubation tanks respectively. As a comparison, incubation solutions containing single drugs, selexicam, and selexicam combined with sildenafil were also prepared. The final drug concentrations in the incubation solutions are shown in Table 1. The pulmonary artery vascular ring was added to the incubation solutions containing the drug, and the changes in the tension of the pulmonary artery ring were recorded. The minimum tension after drug action was measured.
[0071] S4: After observing the maximum efficacy of the drug, replace the incubation solution containing the drug with the basic incubation solution to restore the pulmonary artery ring tension to the basic level.
[0072] 2. Calculate the ring tension suppression rate using the following formula: .
[0073] The ring tension inhibition rate of the combination of PGI2 receptor agonist compound and sildenafil (4:1) is shown in Table 1.
[0074] 3. By inputting the concentrations of the PGI2 receptor agonist compound and its corresponding ring tension inhibition rate, the concentration of sildenafil and its corresponding ring tension inhibition rate, and the concentrations of the PGI2 receptor agonist compound and sildenafil in combination and their corresponding ring tension inhibition rates, the combination drug index (CI) at each concentration ratio is calculated using Compusym software. A Fa-CI curve is plotted with the ring tension inhibition rate (Fa) of the PGI2 receptor agonist compound and sildenafil combination as the x-axis and the combination drug index (CI) as the y-axis.
[0075] The results of the combined drug use index (CI) experiment are shown in Table 2, and the Fa-CI curves are shown in [reference needed]. Figure 1 .
[0076] Table 1. Ring tension inhibition rates of different concentrations of single-drug PGI2 receptor agonist compound, single-drug sildenafil, and combination of PGI2 receptor agonist compound and sildenafil (4:1) in isolated pulmonary artery ring tension comparison test.
[0077] Table 2. Combination index (CI) of different concentrations of PGI2 receptor agonist compounds and sildenafil in different proportions in the isolated pulmonary artery ring tension comparison test (n=5)
[0078] Conclusion: The combination of PGI2 receptor agonist compounds and sildenafil was tested at 5 concentrations in 3 different ratios to measure the inhibition rate of ring tension in isolated pulmonary artery rings. When CI was less than 1, the two drugs had a synergistic effect, and the lower the CI value, the stronger the synergistic effect. When CI was equal to 1, the two drugs had an additive effect. When CI was greater than 1, the two drugs had an antagonistic effect.
[0079] At three ratios (referring to a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3, 4:1, and 10:1, the same below) and five concentrations (as shown in Table 2, referring to five test concentrations corresponding to each PGI2 receptor agonist compound, such as SYN001 concentrations of 0.1 μM, 0.2 μM, 0.4 μM, 0.8 μM, and 1.6 μM, and SYN002 concentrations of 1 μM, 2 μM, 4 μM, 8 μM, and 16 μM, not the sildenafil concentration, which is calculated based on the corresponding combination drug ratio, the same below), the combination index (CI) values of SYN001, SYN002, and sildenafil were all no higher than 0.7, indicating a synergistic effect. Particularly at the 4:1 ratio of the five concentrations, the CI values were even lower, all no higher than 0.6. In the comparative studies, CI values greater than 1 were observed at both the 10:1 and 1:3 ratios, with most CI values exceeding 0.9. At the 4:1 ratio, CI values ranged from approximately 0.77 to 0.96. This indicates that at molar ratios of PGI2 receptor agonist compounds to sildenafil of 1:3–10:1, the synergistic effect of SYN001 at concentrations of 0.1–1.6 μM and SYN002 at concentrations of 1–16 μM on inhibiting the ring tension of isolated pulmonary artery rings was significantly superior to that of the comparative studies.
[0080] At 3 ratios and 5 concentrations, the CI values for the combination of SYN003, SYN004, and sildenafil were all no higher than 0.8, indicating a synergistic effect. Particularly at the 4:1 ratio and 5 concentrations, the CI values were even lower, all no higher than 0.7. This is significantly lower than the CI data of the comparative study, suggesting that at molar ratios of PGI2 receptor agonist compounds to sildenafil of 1:3–10:1, the synergistic effect of SYN003 and SYN004 in inhibiting the ring tension of isolated pulmonary artery rings at concentrations of 1 μM–16 μM is also significantly better than that of the comparative study.
[0081] At 3 ratios and 5 concentrations, the CI values of the combination of SYN013 and sildenafil were all no higher than 0.8, indicating a synergistic effect. In particular, at the 4:1 ratio and 5 concentrations, the CI values were even lower, all no higher than 0.7. At a SYN013 to sildenafil molar ratio of 1:3 and five test concentrations (SYN013 concentrations of 1 μM, 2 μM, 4 μM, 8 μM, and 16 μM), the CI value of SYN013 to sildenafil was below 0.8, while the CI value of the comparative sample was between 0.94 and 1.04 under the same conditions. The CI value of the combination index of SYN013 and sildenafil was significantly lower than that of the comparative sample, indicating a significantly better synergistic effect. At a SYN013 to sildenafil molar ratio of 4:1 and at SYN013 concentrations of 1 μM, 2 μM, 4 μM, and 16 μM, the CI value of the combination index of SYN013 and sildenafil was below 0.6, while the CI value of the comparative sample was between 0.77 and 0.96 under the same conditions. The CI value of the combination index of SYN013 and sildenafil was significantly lower than that of the comparative sample, indicating a significantly better synergistic effect. At a SYN013 to sildenafil molar ratio of 10:1 and at SYN013 concentrations of 1 μM, 2 μM, 4 μM, and 16 μM, the combination index (CI) of SYN013 and sildenafil ranged from 0.55 to 0.72, while the CI of the control group ranged from 0.94 to 1.04 under the same conditions. The CI value of the combination index of SYN013 and sildenafil was significantly lower than that of the control group, indicating that the synergistic effect was significantly better than that of the control group. This suggests that at SYN013 to sildenafil molar ratios of 1:3 to 10:1 and SYN013 concentrations of 1 μM to 4 μM and 16 μM, or at SYN013 to sildenafil molar ratios of 1:3 and SYN013 concentration of 8 μM, the synergistic effect of the combination of SYN013 and sildenafil on the inhibition of ring tension in isolated pulmonary artery rings was significantly better than that of the control group.
[0082] At three ratios and five concentrations, the combination index (CI) values of SYN007, SYN010, and sildenafil were all below 1, indicating a synergistic effect. Particularly at a 10:1 ratio and a concentration of 32 μM, the CI values were 0.58 and 0.66, respectively, while the comparative example had a CI of 0.9 under the same conditions. At this concentration ratio, the CI value of the combination index of SYN007, SYN010, and sildenafil was even lower, demonstrating a significantly better synergistic effect in inhibiting the ring tension of isolated pulmonary artery rings than the comparative example. At a 4:1 ratio and concentrations of 16 μM and 32 μM, the CI values of the combination index of SYN007, SYN010, and sildenafil were below 0.6, while the comparative example had a CI of around 0.8 under the same conditions. At this concentration ratio, the combination index (CI) of SYN007, SYN010, and sildenafil was lower, indicating a significantly better synergistic effect than the control group. At a 1:3 ratio, 16 μM, and 32 μM concentrations, the CI of the combination of SYN007, SYN010, and sildenafil was below 0.75, while the CIs of the control group were 1.02 and 0.94, respectively, under the same conditions. At this concentration ratio, the CI of the combination of SYN007, SYN010, and sildenafil was lower, indicating a significantly better synergistic effect on inhibiting the ring tension of isolated pulmonary artery rings than the control group.
[0083] At a 1:3 ratio and a concentration of 16 μM, the CI value of the combination of SYN005 and sildenafil was 0.77, which was significantly lower than the CI value of 1.02 of the control group under the same conditions. At this ratio and concentration, the synergistic effect of SYN005 and sildenafil in inhibiting the ring tension of isolated pulmonary artery rings was significantly better than that of the control group.
[0084] At a 4:1 ratio and a concentration of 2 μM, the CI value of the combination of SYN006 and sildenafil was 0.81, which was significantly lower than the CI value of 0.96 of the control group under the same conditions. At this ratio and concentration, the synergistic effect of SYN006 and sildenafil in inhibiting the ring tension of isolated pulmonary artery rings was significantly better than that of the control group.
[0085] At a 1:3 ratio and a concentration of 16 μM, the CI value of the combination of SYN008 and sildenafil was 0.91, which was lower than the CI value of 1.02 of the control group under the same conditions. At this ratio and concentration, the synergistic effect of SYN008 and sildenafil was better than that of the control group, and the control group had no synergistic effect and showed a certain antagonistic effect.
[0086] At a 4:1 ratio and a concentration of 32 μM, the CI value of the combination of SYN017 and sildenafil was 0.5, significantly lower than the CI value of 0.82 of the control group under the same conditions (32 μM). At a 10:1 ratio and a concentration of 32 μM, the CI value of the combination of SYN017 and sildenafil was 0.67, significantly lower than the CI value of 0.90 of the control group under the same conditions. At a 1:3 ratio and a concentration of 32 μM, the CI value of the combination of SYN017 and sildenafil was 0.62, significantly lower than the CI value of 0.94 of the control group under the same conditions. At the above ratios and corresponding concentrations, the synergistic effect of the combination of SYN017 and sildenafil on inhibiting the ring tension of isolated pulmonary artery rings was significantly better than that of the control group.
[0087] At a 4:1 ratio and a concentration of 32 μM, the CI value of the combination of SYN044 and sildenafil was 0.41, significantly lower than the CI value of 0.82 for the control group under the same conditions. At this concentration ratio, the synergistic effect of SYN044 and sildenafil was significantly better than that of the control group. At a 1:3 ratio and a concentration of 32 μM, the CI value of the combination of SYN044 and sildenafil was 0.56, significantly lower than the CI value of 0.94 for the control group under the same conditions. At this concentration ratio, the synergistic effect of SYN044 and sildenafil in inhibiting the ring tension of isolated pulmonary artery rings was significantly better than that of the control group.
[0088] At a 4:1 ratio and a concentration of 8 μM, the CI value of the combination of SYN045 and sildenafil was 0.5, significantly lower than the CI value of 0.82 for the control group under the same conditions (32 μM concentration) and 0.86 for the control group at the same concentration (8 μM). At a 10:1 ratio and a concentration of 8 μM, the CI value of the combination of SYN045 and sildenafil was 0.65, significantly lower than the CI value of 0.90 for the control group under the same conditions (32 μM concentration) and 0.94 for the control group at the same concentration. At a 1:3 ratio and a concentration of 8 μM, the CI value of the combination of SYN045 and sildenafil was 0.6, significantly lower than the CI value of 0.94 for the control group under the same conditions (32 μM concentration) and 0.96 for the control group at the same concentration. At the above ratios and corresponding concentrations, the synergistic effect of the combination of SYN045 and sildenafil on the inhibition of ring tension in isolated pulmonary artery rings was significantly better than that of the control group.
[0089] At a 4:1 ratio and a concentration of 4 μM, the CI value of the combination of SYN046 and sildenafil was 0.55, significantly lower than the CI value of 0.77 for the control group under the same conditions (16 μM concentration) and 0.89 for the control group at the same concentration (4 μM concentration). At a 1:3 ratio and a concentration of 4 μM, the CI value of the combination of SYN046 and sildenafil was 0.7, significantly lower than the CI value of 1.02 for the control group under the same conditions (16 μM concentration) and 0.98 for the control group at the same concentration (4 μM concentration). At the above ratios and corresponding concentrations, the synergistic effect of the combination of SYN046 and sildenafil on inhibiting the ring tension of isolated pulmonary artery rings was significantly better than that of the control group.
[0090] At a 4:1 ratio and concentrations of 16 μM and 32 μM, the CI values of the combination of SYN018 and sildenafil were 0.59 and 0.44, respectively, significantly lower than the CI values of the control group (0.77 and 0.82) under the same conditions (16 μM and 32 μM). At a 10:1 ratio and concentration of 32 μM, the CI value of the combination of SYN018 and sildenafil was 0.61, significantly lower than the CI value of the control group (0.90) under the same conditions. At a 1:3 ratio and concentrations of 16 μM and 32 μM, the CI values of the combination of SYN018 and sildenafil were 0.72 and 0.6, respectively, significantly lower than the CI values of the control group (1.02 and 0.94) under the same conditions. At the above ratios and corresponding concentrations, the synergistic effect of the combination of SYN018 and sildenafil on inhibiting the ring tension of isolated pulmonary artery rings was significantly better than that of the control group.
[0091] The above results indicate that the PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045, and SYN046, when used in combination with sildenafil at the specific ratios and test concentrations mentioned above, have a synergistic effect in inhibiting K+-induced increases in pulmonary artery ring tension. This synergistic effect is superior to that of selexipag combined with sildenafil. Among these, SYN001, SYN002, and SYN005 have a synergistic effect. The synergistic effect of YN003, SYN004, and SYN013 in combination with sildenafil is more prominent. The synergistic effect is better than that of the control group at 3 ratios and 5 test concentrations. This indicates that the synergistic effect of SYN001, SYN002, SYN003, SYN004, and SYN013 in combination with sildenafil at molar ratios of 1:3-10:1, SYN001 at concentrations of 0.1μM-1.6μM, and SYN002, SYN003, SYN004, and SYN013 at concentrations of 1μM-16μM on inhibiting the proliferation of human pulmonary artery smooth muscle cells is very significant.
[0092] Experimental Example 2: Comparative Study on the Inhibition Rate of Human Pulmonary Artery Smooth Muscle Cell Proliferation by Combination of PGI2 Receptor Agonists and Sildenafil Evaluating drug efficacy using cell models reveals that excessive proliferation and migration of pulmonary artery smooth muscle cells (PASMCs) are prominent features of vascular remodeling. In PAH, pulmonary vascular smooth muscle cells transform from a contractile phenotype to a proliferative synthetic phenotype, primarily manifested as cell proliferation and hypertrophy. These pathological changes ultimately lead to pulmonary vascular lumen narrowing and decreased wall compliance, thereby promoting the development and progression of PAH. Therefore, PASMCs can be used for drug screening in pulmonary hypertension. The PDGF-induced human pulmonary artery smooth muscle cell proliferation model is a classic model for evaluating pulmonary hypertension therapeutic drugs at the cellular level.
[0093] The experimental drugs, PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045, and SYN046, and the control drug, PGI2 receptor agonist selexiparg, were combined with sildenafil at molar ratios of 10:1, 4:1, and 1:3, respectively, to conduct a comparative experiment on the inhibition rate of human pulmonary artery smooth muscle cell proliferation, in order to investigate the effect of the combined use of PGI2 receptor agonist compounds and sildenafil on PDGF-induced human pulmonary artery smooth muscle cell proliferation.
[0094] Experimental procedure: Control group preparation: Human pulmonary artery smooth muscle cells were digested with 0.25% trypsin solution, seeded at 6×103 / well in 96-well plates (final volume 100μL) and cultured for 24h. Then, they were starved in serum-free Dulbecco's modified eagle medium (DMEM) high glucose medium for 24h. 100μL of DMEM was added again and cultured for 24h to obtain the control group.
[0095] Model group preparation: Human pulmonary artery smooth muscle cells were digested with 0.25% trypsin solution and seeded at 6 × 10³ cells / well in 96-well plates (final volume 100 μL). After culturing for 24 h, the cells were starved in serum-free Dulbecco's modified eagle medium (DMEM) high-glucose medium for 24 h. Then, 100 μL of DMEM containing human platelet-derived growth factor (hPDGF-BB) was added to a final concentration of 20 ng / mL and cultured for 24 h to obtain the model group.
[0096] Preparation of the test group: Human pulmonary artery smooth muscle cells were digested with 0.25% trypsin solution and seeded at 6 × 10³ cells / well in 96-well plates (final volume 100 μL). After culturing for 24 h, the cells were starved in serum-free Dulbecco's modified eagle medium (DMEM) high-glucose medium for 24 h. Human platelet-derived growth factor (hPDGF-BB) was added to DMEM to a final concentration of 20 ng / mL. The pre-prepared single-drug solutions of different concentrations of PGI2 receptor agonist compounds, sildenafil single-drug solutions, and combined solutions of PGI2 receptor agonist compounds and sildenafil were then serially diluted with DMEM containing hPDGF-BB to the concentrations shown in Tables 3 and 4 to obtain the test solutions. The test solutions were added to the starved cell culture wells at a volume of 100 μL and cultured for 24 h to obtain the test group.
[0097] CellTiter-Glo reagent was added to the culture wells of the test group, control group, and model group. The luminescence value was measured, cell viability was detected, and the cell proliferation inhibition rate was calculated.
[0098] Formula for calculating cell proliferation inhibition rate: .
[0099] By inputting the concentrations of PGI2 receptor agonist compounds and their corresponding cell proliferation inhibition rates, the concentrations of sildenafil and their corresponding cell proliferation inhibition rates, and the concentrations of PGI2 receptor agonist compounds and sildenafil in combination and their corresponding cell proliferation inhibition rates, the combination drug index CI was calculated using Compusym software at each concentration ratio. A Fa-CI curve was plotted with the cell proliferation inhibition rate Fa of the combination of PGI2 receptor agonist compounds and sildenafil as the x-axis and the combination drug index CI as the y-axis.
[0100] The experimental results are shown in Tables 3 and 4. Figure 2 .
[0101] Table 3. Cell proliferation inhibition rates of different concentrations of single-drug PGI2 receptor agonist compound, single-drug sildenafil, and combination therapy of PGI2 receptor agonist compound and sildenafil (1:3) in a comparative experiment on the inhibition rate of human pulmonary artery smooth muscle cell proliferation.
[0102] Table 4. Combination index (CI) of different concentrations of PGI2 receptor agonist compounds and sildenafil in different proportions during a comparative study on the inhibition rate of human pulmonary artery smooth muscle cell proliferation (n=5).
[0103] Conclusion: The combination index (CI) of PGI2 receptor agonist compounds and sildenafil was tested at 5 concentrations in 3 different ratios to measure the inhibition rate of human pulmonary artery smooth muscle cell proliferation. When CI was less than 1, the two drugs had a synergistic effect, and the lower the CI value, the stronger the synergistic effect. When CI was equal to 1, the two drugs had an additive effect. When CI was greater than 1, the two drugs had an antagonistic effect.
[0104] At three ratios (molar ratios of PGI2 receptor agonist compound to sildenafil of 1:3, 4:1, and 10:1, the same below) and five concentrations (as shown in Table 4, referring to five test concentrations of the PGI2 receptor agonist compound, such as SYN005 concentrations of 0.1 μM, 0.3 μM, 0.9 μM, 2.7 μM, and 8.1 μM, not the sildenafil concentration, which was calculated based on the corresponding combination drug ratio, the same below), the combination index (CI) values of SYN005 and sildenafil were all no higher than 0.7, indicating a synergistic effect. Particularly at the 4:1 ratio of the five concentrations, the CI values were even lower, all no higher than 0.6. In the comparative studies, CI values greater than 1 were observed at ratios of 1:3 and 10:1, with most CI values approaching 0.9 or higher. However, at a 4:1 ratio, the CI values ranged from approximately 0.68 to 0.87. Under the same conditions, the CI values were significantly higher than those of the combination of SYN005 and sildenafil. This indicates that the synergistic effect of the combination of SYN005 and sildenafil on inhibiting the proliferation of human pulmonary artery smooth muscle cells was significantly better than that of the comparative studies when the molar ratio of the PGI2 receptor agonist compound to sildenafil was 1:3-10:1 and the concentration of the PGI2 receptor agonist compound was 0.1 μM-8.1 μM.
[0105] At 3 ratios and 5 concentrations, the CI values for the combination of SYN001, SYN018, and sildenafil were all no higher than 0.8, indicating a synergistic effect. Particularly at the 4:1 ratio and 5 concentrations, the CI values were even lower, all no higher than 0.65. Compared to the control group, these CI values were significantly lower, suggesting that the synergistic effect of SYN001, SYN018, and sildenafil on inhibiting the proliferation of human pulmonary artery smooth muscle cells was also significantly better than the control group at molar ratios of PGI2 receptor agonist compounds to sildenafil of 1:3–10:1 and concentrations of the PGI2 receptor agonist compound of 0.1 μM–8.1 μM.
[0106] At three ratios and five concentrations, the CI values of the combination of SYN002 and sildenafil were all no higher than 1, indicating a synergistic effect. Particularly at the three ratios and a concentration of 8.1 μM, the CI values were all no higher than 0.5, and even lower than the control group CI data under the same conditions. This suggests that at a molar ratio of 1:3 to 10:1 between the PGI2 receptor agonist compound and sildenafil, and a PGI2 receptor agonist compound concentration of 8.1 μM, the synergistic effect of SYN002 combined with sildenafil on the inhibition of human pulmonary artery smooth muscle cell proliferation was significantly better than that of the control group.
[0107] At three ratios and five concentrations, the CI values of the combination of SYN003 and sildenafil were all no higher than 0.85, indicating a synergistic effect. Particularly at the three ratios and concentrations of 0.1 μM and 2.7 μM, the CI values were all no higher than 0.81, and even lower than the control group CI data under the same conditions. This suggests that at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3–10:1 and at PGI2 receptor agonist compound concentrations of 0.1 μM and 2.7 μM, the synergistic effect of SYN003 combined with sildenafil on the inhibition of human pulmonary artery smooth muscle cell proliferation was significantly better than that of the control group.
[0108] The CI values of SYN004 combined with sildenafil exceeded 1 at multiple ratios and test concentrations, indicating no synergistic effect. However, at a 10:1 ratio and a concentration of 0.1 μM, its CI value was 0.82, significantly lower than the CI value of 1.02 of the control group under the same conditions. This suggests that at a 10:1 ratio and a PGI2 receptor agonist compound concentration of 0.1 μM, the synergistic effect of SYN004 combined with sildenafil on the inhibition of human pulmonary artery smooth muscle cell proliferation was significantly better than that of the control group.
[0109] The CI values of SYN006 combined with sildenafil exceeded 1 at several test concentrations in various ratios, indicating no synergistic effect. However, at three ratios and a concentration of 2.7 μM, the CI values were all no higher than 0.71, and were lower than the CI values of the control group under the same conditions. This suggests that at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3-10:1 and a PGI2 receptor agonist compound concentration of 2.7 μM, the synergistic effect of SYN006 combined with sildenafil on the inhibition of human pulmonary artery smooth muscle cell proliferation is significantly better than that of the control group.
[0110] At three ratios and five concentrations, the CI values of the combination of SYN007 and sildenafil were all no higher than 0.85, indicating a synergistic effect. Particularly at the three ratios and concentrations of 0.1 μM and 8.1 μM, the CI values were all no higher than 0.61, and even lower than the control group CI data under the same conditions. This suggests that at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3-10:1 and at PGI2 receptor agonist compound concentrations of 0.1 μM and 8.1 μM, the synergistic effect of SYN007 combined with sildenafil on the inhibition of human pulmonary artery smooth muscle cell proliferation is significantly better than that of the control group.
[0111] At three ratios and five concentrations, the CI values for the combination of SYN008, SYN010, and sildenafil were all no higher than 0.85, indicating a synergistic effect. Particularly at the three ratios and concentrations of 0.1 μM and 0.3 μM, the CI values were all no higher than 0.75, and even lower than the control group CI data under the same conditions. This suggests that at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3–10:1 and at PGI2 receptor agonist compound concentrations of 0.1 μM and 0.3 μM, the synergistic effect of SYN008, SYN010, and sildenafil in inhibiting the proliferation of human pulmonary artery smooth muscle cells was significantly better than that in the control group.
[0112] The CI value of SYN013 combined with sildenafil at a certain ratio and test concentration was 1, indicating no synergistic effect. However, at three ratios and concentrations of 2.7 μM and 8.1 μM, the CI values were all no higher than 0.75, and were lower than the CI data of the control group under the same conditions. This indicates that at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3-10:1 and at PGI2 receptor agonist compound concentrations of 2.7 μM and 8.1 μM, the synergistic effect of SYN013 combined with sildenafil on the inhibition of human pulmonary artery smooth muscle cell proliferation is significantly better than that of the control group.
[0113] At a certain ratio and test concentration, the CI value of SYN017 combined with sildenafil exceeded 1, indicating no synergistic effect. However, at three ratios and a concentration of 0.3 μM, the CI value was no higher than 0.7, and was even lower than the CI data of the control group under the same conditions. This suggests that at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3-10:1 and a concentration of PGI2 receptor agonist compound of 0.3 μM, the synergistic effect of SYN017 combined with sildenafil on the inhibition of human pulmonary artery smooth muscle cell proliferation is significantly better than that of the control group.
[0114] At three ratios and five concentrations, the CI values of the combination of SYN044, SYN045, and sildenafil were all no higher than 1, indicating a synergistic effect. Particularly at the three ratios and a concentration of 0.1 μM, the CI values were all no higher than 0.81, and were even lower than the control group CI data under the same conditions. This suggests that at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3-10:1 and a PGI2 receptor agonist compound concentration of 0.1 μM, the synergistic effect of SYN044, SYN045, and sildenafil in inhibiting the proliferation of human pulmonary artery smooth muscle cells was significantly better than that in the control group.
[0115] At three ratios and five concentrations, the CI values of the combination of SYN046 and sildenafil were all no higher than 1, indicating a synergistic effect. Particularly at the three ratios and a concentration of 2.7 μM, the CI values were all no higher than 0.52, and even lower than the control group CI data under the same conditions. This suggests that at a molar ratio of PGI2 receptor agonist compound to sildenafil of 1:3-10:1 and a PGI2 receptor agonist compound concentration of 2.7 μM, the synergistic effect of SYN046 combined with sildenafil on the inhibition of human pulmonary artery smooth muscle cell proliferation is significantly better than that of the control group.
[0116] The above results indicate that the PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045, and SYN046, when used in combination with sildenafil at the specific ratios and test concentrations mentioned above, exhibit a synergistic effect in inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells. The combination of SYN001, SYN005, and SYN018 with sildenafil showed superior results compared to the control group. The synergistic effect of SYN001, SYN005, and SYN018 with sildenafil was more pronounced, with the synergistic effect being better than that of the control group at 3 ratios and 5 test concentrations. This indicates that the combination of SYN001, SYN005, and SYN018 with sildenafil at molar ratios of 1:3-10:1 and PGI2 receptor agonist compound concentrations of 0.1 μM-8.1 μM has a very significant synergistic effect on inhibiting the proliferation of human pulmonary artery smooth muscle cells.
[0117] In summary, the PGI2 receptor agonist compounds SYN001, SYN002, SYN003, SYN004, SYN005, SYN006, SYN007, SYN008, SYN010, SYN013, SYN017, SYN018, SYN044, SYN045, and SYN046, when used in combination with sildenafil at the specific ratios and test concentrations described above, exhibit a synergistic effect in inhibiting K+-induced pulmonary artery ring tension increase and / or inhibiting PDGF-induced human pulmonary artery smooth muscle cell proliferation. Furthermore, this synergistic effect is superior to that of selexipag combined with sildenafil.
[0118] Among them, SYN001, SYN002, SYN003, SYN004, and SYN013, when used in combination with sildenafil, showed a more pronounced synergistic effect in inhibiting K+-induced increases in pulmonary artery ring tension, with superior synergistic effects compared to the control group at all three ratios and five tested concentrations. Furthermore, SYN001, SYN005, and SYN018, when used in combination with sildenafil, showed a more pronounced synergistic effect in inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells, with superior synergistic effects compared to the control group at all three ratios and five tested concentrations. Therefore, compound SYN001 exhibits significant synergistic effects in both aspects: a strong synergistic effect in inhibiting K+-induced increases in pulmonary artery ring tension and a strong synergistic effect in inhibiting PDGF-induced proliferation of human pulmonary artery smooth muscle cells. The aforementioned PGI2 receptor agonist compounds, when used in combination with sildenafil, show broad application prospects in the treatment of pulmonary hypertension.
[0119] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions or improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A pharmaceutical composition, characterized in that, It includes a first active ingredient and a second active ingredient, wherein the first active ingredient is a PGI2 receptor agonist compound represented by general formula II or III or a pharmaceutically acceptable salt thereof, and the second active ingredient is sildenafil; In general formulas II and III, R1 and R2 are selected from H, methyl, or F; Z represents an N atom, or Z represents CR7 and R7 represents H; R3 is isopropyl; R5 is selected from OH or NHSO2CH3; In the general formula III, R4 is selected from H, methoxy, ethoxy, or... ; The molar ratio of the first active ingredient to the second active ingredient is 1:4-12:
1.
2. The pharmaceutical composition according to claim 1, characterized in that, The first active ingredient is selected from specific compounds (1)-(15) with the following structural formulas: 。 3. The pharmaceutical composition according to any one of claims 1-2, characterized in that, The molar ratio of the first active ingredient to the second active ingredient is 1:3-10:
1.
4. The pharmaceutical composition according to claim 3, characterized in that, The molar ratio of the first active ingredient to the second active ingredient is 1:3, 4:1 or 10:
1.
5. The pharmaceutical composition according to claim 4, characterized in that, The first active ingredient is a specific compound (1), wherein the molar ratio of the specific compound (1) to sildenafil is 1:3, 4:1, or 10:1; or The first active ingredient is a specific compound (2), wherein the molar ratio of the specific compound (2) to sildenafil is 1:3, 4:1, or 10:1; or The first active ingredient is a specific compound (3), wherein the molar ratio of the specific compound (3) to sildenafil is 1:3, 4:1, or 10:1; or The first active ingredient is a specific compound (11), wherein the molar ratio of the specific compound (11) to sildenafil is 1:3, 4:1, or 10:1; or The first active ingredient is a specific compound (15), and the molar ratio of the specific compound (15) to sildenafil is 1:3, 4:1 or 10:
1.
6. The pharmaceutical composition according to claim 4, characterized in that, The first active ingredient is a specific compound (12), wherein the molar ratio of the specific compound (12) to sildenafil is 1:3 or 4:1; or The first active ingredient is a specific compound (13), wherein the molar ratio of the specific compound (13) to sildenafil is 1:3 or 4:1; or The first active ingredient is a specific compound (14), and the molar ratio of the specific compound (14) to sildenafil is 1:3 or 4:
1.
7. The pharmaceutical composition according to claim 4, characterized in that, The first active ingredient is a specific compound (4), wherein the molar ratio of the specific compound (4) to sildenafil is 10:1; or The first active ingredient is a specific compound (5), wherein the molar ratio of the specific compound (5) to sildenafil is 1:3; or The first active ingredient is a specific compound (6), wherein the molar ratio of the specific compound (6) to sildenafil is 4:1; or The first active ingredient is a specific compound (7), wherein the molar ratio of the specific compound (7) to sildenafil is 10:1; or The first active ingredient is a specific compound (8), wherein the molar ratio of the specific compound (8) to sildenafil is 1:3; or The first active ingredient is a specific compound (9), wherein the molar ratio of the specific compound (9) to sildenafil is 1:3; or The first active ingredient is a specific compound (10), and the molar ratio of the specific compound (10) to sildenafil is 10:
1.
8. The pharmaceutical composition according to any one of claims 1-2 and 4-7, characterized in that, It also includes acceptable carriers and / or excipients, and the pharmaceutical composition is in the form of tablets, granules, capsules, powders, or injections.
9. Use of a pharmaceutical composition according to any one of claims 1-8 in the preparation of a combination medicament for treating pulmonary arterial hypertension.
Citation Information
Patent Citations
Diphenyltriazine compound as well as preparation method and application thereof
CN118598820A
Pgi2 receptor agonist compounds, pharmaceutical compositions and uses
CN118619893B
